The company announced on 18 February that the trial did not meet its primary endpoint measured by a depression rating scale, ...

After the rejection of Lykos Therapeutics’ MDMA-based PTSD treatment tempered excitement for psychedelic therapeutics, a ...

FDA's rejection of MDMA therapy for PTSD doesn't dampen hopes for other psychedelic treatments. Read more here.

Q4 2024 Earnings Call Transcript February 7, 2025 Operator: Ladies and gentlemen, thank you for standing by. Welcome to ...

In Pharma, you've heard us talk about our Nasal Bidose System for Johnson & Johnson Spravato medication to treat treatment-resistant depression. Recently, the FDA approved Spravato as a monomer ...

The Food and Drug Administration (FDA) recently expanded approval for Spravato, an antidepressant nasal spray used to treat depression. Parkside Psychiatric Hospital has a Spravato outpatient clinic ...

Ketamine has been used as an anesthetic before surgeries for decades, but it can also be an option for those struggling with depression and suicidal thoughts- especially when anti-depressants and talk ...

The Food and Drug Administration (FDA) recently expanded approval for Spravato, an antidepressant nasal spray used to treat depression. Parkside Psychiatric Hospital has a Spravato outpatient ...

It can occur with prescription or nonprescription drugs. It can also range from mild to severe. Substance use disorder, formerly known as “drug abuse,” develops when substance use interferes ...

Now, the new FDA approval means that patients will be able use the ketamine-derived nasal spray, which is marketed under the brand name Spravato, without having to be on another type of antidepressant ...

A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...